Recombinant human alpha-1 antitrypsin (rEVO Biologics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human alpha-1 antitrypsin (rEVO Biologics)
Drug Alias NamerhAAT (rEVO Biologics)
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionLeukocyte elastase inhibitors
TargetsLeukocyte elastase
Therapy Area/Indicationsalpha 1-Antitrypsin Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLfb Biotechnologies Sas
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLfb Biotechnologies Sas
Active IndicationsN/A
Inactive Indicationsalpha 1-Antitrypsin Deficiency

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank